Publications
- Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis2021 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis2021 | First Faculty of Medicine
- Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis2021 | First Faculty of Medicine
- Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis2021 | First Faculty of Medicine
- Monitoring of radiologic disease activity by serum neurofilaments in MS +12020 | First Faculty of Medicine
- Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study2020 | First Faculty of Medicine
- Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?2017 | First Faculty of Medicine
- Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis2017 | First Faculty of Medicine
- Serum lipid profile changes predict neurodegeneration in interferon-beta 1a-treated multiple sclerosis patients2017 | First Faculty of Medicine
- Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients2017 | First Faculty of Medicine
Loading network view...